Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2012 1
2013 2
2014 1
2015 1
2016 2
2018 1
2019 3
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG, de Moura Ferreira G, Lupi LA, da Silva Nunes I, Fávaro WJ. de Almeida Chuffa LG, et al. J Ovarian Res. 2018 Jan 17;11(1):8. doi: 10.1186/s13048-018-0380-5. J Ovarian Res. 2018. PMID: 29343281 Free PMC article.
RESULTS: Although CIS therapy was more effective than P-MAPA in reducing the tumor size, P-MAPA immunotherapy significantly increased the expressions of TLR2 and TLR4. More importantly, the combination of P-MAPA with CIS showed a greater …
RESULTS: Although CIS therapy was more effective than P-MAPA in reducing the tumor size, P-MAPA immunotherapy si …
P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in Ovarian Cancer SKOV-3 Cells: A Preliminary Study.
Lupi LA, Delella FK, Cucielo MS, Romagnoli GG, Kaneno R, Nunes IDS, Domeniconi RF, Martinez M, Martinez FE, Fávaro WJ, Chuffa LGA. Lupi LA, et al. Molecules. 2019 Dec 18;25(1):5. doi: 10.3390/molecules25010005. Molecules. 2019. PMID: 31861351 Free PMC article.
P-MAPA and IL-12 showed cancer cell toxicity under low doses after 48 h. Although apoptosis/necrosis and the cell cycle were unchanged by the treatments, P-MAPA enhanced the sensitivity to paclitaxel (PTX) and P-MAPA associated with IL-12
P-MAPA and IL-12 showed cancer cell toxicity under low doses after 48 h. Although apoptosis/necrosis and the cell cycle were u
P-MAPA and IL-12 Differentially Regulate Proteins Associated with Ovarian Cancer Progression: A Proteomic Study.
Júnior LAL, Cucielo MS, Domeniconi RF, Dos Santos LD, Silveira HS, da Silva Nunes I, Martinez M, Martinez FE, Fávaro WJ, Chuffa LGA. Júnior LAL, et al. ACS Omega. 2019 Dec 11;4(26):21761-21777. doi: 10.1021/acsomega.9b02512. eCollection 2019 Dec 24. ACS Omega. 2019. PMID: 31891054 Free PMC article.
Herein, the effects of the protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride, known as P-MAPA, and the human recombinant interleukin-12 (hrIL-12) were tested alone or in combination in human SKOV-3 cells. The doses and period were defined …
Herein, the effects of the protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride, known as P-MAPA, and …
P-mapa, a promisor immunomodulator against tumor cells of colonic tissues: An investigation of the action mechanism over the TLR4 signaling pathway.
Socca EAR, Reis SK, Genaro SC, Leite SK, Reis IB, Bockëlmann PK, Durán N, Fávaro WJ. Socca EAR, et al. Life Sci. 2020 Feb 1;242:117185. doi: 10.1016/j.lfs.2019.117185. Epub 2019 Dec 18. Life Sci. 2020. PMID: 31862453
The present results show the immunomodulatory properties of P-mapa in chemically induced CRC model. P-mapa induced a significant increase in Type-I IFNs synthesis and subsequently immune cell recruitment, resulting in an increase of IFNγ concentration …
The present results show the immunomodulatory properties of P-mapa in chemically induced CRC model. P-mapa induc …
Effects of P-MAPA immunomodulator on Toll-like receptor 2, ROS, nitric oxide, MAPKp38 and IKK in PBMC and macrophages from dogs with visceral leishmaniasis.
Melo LM, Perosso J, Almeida BF, Silva KL, Somenzari MA, de Lima VM. Melo LM, et al. Int Immunopharmacol. 2014 Feb;18(2):373-8. doi: 10.1016/j.intimp.2013.12.012. Epub 2013 Dec 24. Int Immunopharmacol. 2014. PMID: 24374021
-infected dogs compared with healthy dogs and P-MAPA improved ROS production. NO production was increased in culture supernatant from macrophages stimulated by P-MAPA in both healthy and Leishmania spp. infected dogs. ...These findings suggest that …
-infected dogs compared with healthy dogs and P-MAPA improved ROS production. NO production was increased in culture supernata …
Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer.
Fávaro WJ, Nunes OS, Seiva FR, Nunes IS, Woolhiser LK, Durán N, Lenaerts AJ. Fávaro WJ, et al. Infect Agent Cancer. 2012 Jun 18;7(1):14. doi: 10.1186/1750-9378-7-14. Infect Agent Cancer. 2012. PMID: 22709446 Free PMC article.
RESULTS: The results showed that P-MAPA, administered alone or in combination with MXF, induced significant responses in vivo against TB. ...P-MAPA showed a significant stimulatory effect on human TLR2 and TLR4 in vitro. In BC, TLR2, TLR4 and p53 prote …
RESULTS: The results showed that P-MAPA, administered alone or in combination with MXF, induced significant responses in vivo …
Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with p - mapa and systemic administration of cisplatin and doxorubicin.
Dias QC, Nunes ID, Garcia PV, Favaro WJ. Dias QC, et al. Int Braz J Urol. 2016 Sep-Oct;42(5):942-954. doi: 10.1590/S1677-5538.IBJU.2015.0381. Int Braz J Urol. 2016. PMID: 24893914 Free PMC article.
Furthermore, Akt, PI3K, NF-kB and VEGF protein levels were significantly lower in intravesical P-MAPA plus systemic cisplatin and in intravesical P-MAPA alone treatments than other groups. In contrast, PTEN protein levels were significantly higher in i …
Furthermore, Akt, PI3K, NF-kB and VEGF protein levels were significantly lower in intravesical P-MAPA plus systemic cisplatin …
P-MAPA activates TLR2 and TLR4 signaling while its combination with IL-12 stimulates CD4+ and CD8+ effector T cells in ovarian cancer.
Silveira HS, Lupi LA, Romagnoli GG, Kaneno R, da Silva Nunes I, Fávaro WJ, de Almeida Chuffa LG. Silveira HS, et al. Life Sci. 2020 Aug 1;254:117786. doi: 10.1016/j.lfs.2020.117786. Epub 2020 May 18. Life Sci. 2020. PMID: 32433918
We investigated the effects of P-MAPA and IL-12 on the inflammatory and immune responses in a chemically-induced OC model. MAIN METHODS: OCs were induced with 7,12-dimethylbenz(a)anthracene into the ovarian bursa, and the animals were given P-MAPA (5 m …
We investigated the effects of P-MAPA and IL-12 on the inflammatory and immune responses in a chemically-induced OC model. MAI …
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
Garcia PV, Seiva FR, Carniato AP, de Mello Júnior W, Duran N, Macedo AM, de Oliveira AG, Romih R, Nunes Ida S, Nunes Oda S, Fávaro WJ. Garcia PV, et al. BMC Cancer. 2016 Jul 7;16:422. doi: 10.1186/s12885-016-2474-z. BMC Cancer. 2016. PMID: 27389279 Free PMC article.
Interferon signaling pathway activation induced by P-MAPA led to increase of iNOS protein levels, resulting in apoptosis and histopathological recovery. Additionally, P-MAPA immunotherapy increased wild-type p53 protein levels. The increased wild-type …
Interferon signaling pathway activation induced by P-MAPA led to increase of iNOS protein levels, resulting in apoptosis and h …
The P-MAPA immunomodulator partially prevents apoptosis induced by Zika virus infection in THP-1 cells.
Lima MC, Azevedo EAN, de Morais CNL, de Sousa LIO, Carvalho BM, da Silva IN, Franca RFO. Lima MC, et al. Curr Pharm Biotechnol. 2020 Jun 2. doi: 10.2174/1389201021666200602140005. Online ahead of print. Curr Pharm Biotechnol. 2020. PMID: 32484769
OBJECTIVE: To investigate the role of P-MAPA immunomodulator in Zika-infected THP-1 cells. METHODS: THP-1 cells were subjected at Zika virus infection (Multiplicity of Infection = 0.5) followed by treatment with P-MAPA for until 96 hours post-infection …
OBJECTIVE: To investigate the role of P-MAPA immunomodulator in Zika-infected THP-1 cells. METHODS: THP-1 cells were subjected …
13 results
Jump to page
Feedback